Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
C 215.98 -1.72% -3.78
VRTX closed down 1.72 percent on Thursday, April 22, 2021, on approximately normal volume. It was able to find support at its 50 day moving average.
Earnings due: Apr 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical VRTX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.72%
NR7 Range Contraction -1.72%
Upper Bollinger Band Walk Strength -1.72%
Upper Bollinger Band Walk Strength -1.90%
Upper Bollinger Band Touch Strength -1.90%
Slingshot Bullish Bullish Swing Setup -1.46%
Upper Bollinger Band Walk Strength -1.46%
Older End-of-Day Signals for VRTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 17 hours ago
60 Minute Opening Range Breakout about 17 hours ago
Gap Down Partially Closed about 18 hours ago
50 DMA Support about 19 hours ago
20 DMA Support about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vertex Pharmaceuticals Incorporated Description

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Chemical Compounds Organic Compounds Autoimmune Disease Infection Influenza Cystic Fibrosis Serious Diseases Hepatitis C Hepatitis C Virus Breakthrough Therapy Treatment Of Autoimmune Disease HCV Janssen Pharmaceutica Cyclopropanes Organofluorides Treatment Of Cystic Fibrosis Genotype HCV Infection Vertex Pharmaceuticals

Is VRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 306.08
52 Week Low 202.565
Average Volume 1,804,001
200-Day Moving Average 239.07
50-Day Moving Average 214.36
20-Day Moving Average 215.69
10-Day Moving Average 217.56
Average True Range 4.68
ADX 16.42
+DI 17.53
-DI 15.95
Chandelier Exit (Long, 3 ATRs ) 208.75
Chandelier Exit (Short, 3 ATRs ) 223.25
Upper Bollinger Band 221.53
Lower Bollinger Band 209.86
Percent B (%b) 0.52
BandWidth 5.41
MACD Line 1.00
MACD Signal Line 0.57
MACD Histogram 0.4301
Fundamentals Value
Market Cap 56.16 Billion
Num Shares 260 Million
EPS 10.20
Price-to-Earnings (P/E) Ratio 21.17
Price-to-Sales 9.98
Price-to-Book 7.25
PEG Ratio 0.35
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 223.33
Resistance 3 (R3) 223.49 221.19 222.11
Resistance 2 (R2) 221.19 219.32 221.12 221.70
Resistance 1 (R1) 218.59 218.17 217.44 218.43 221.29
Pivot Point 216.29 216.29 215.72 216.22 216.29
Support 1 (S1) 213.69 214.42 212.54 213.53 210.67
Support 2 (S2) 211.39 213.27 211.32 210.26
Support 3 (S3) 208.79 211.39 209.86
Support 4 (S4) 208.63